Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of July 2026. The document serves as a transaction notification regarding a purchase of company securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It is a regulatory disclosure of a specific executive transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of American Depositary Shares (ADS) |
| Instrument ISIN | US37733W2044 |
| Transaction Price | $53.3200 per ADS |
| Volume | 8.9550 ADS |
| Transaction Date | July 7, 2026 |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely details an initial notification of an acquisition within the GSK Executive Supplemental Savings Plan account.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It is a standard compliance report for insider trading activity.
Key Facts for Investor Verification
- Executive Identity: The transaction was executed by Maya Martinez-Davis, President of GSK US.
- Transaction Nature: The purchase was made through the GSK Executive Supplemental Savings Plan, not a direct open-market purchase.
- Volume Significance: The volume of 8.9550 ADS represents a nominal value (approximately $477), indicating a routine plan contribution rather than a significant strategic position change.
- Market Price: The transaction price of $53.32 reflects the market value of GSK ADS on July 7, 2026.